Nuvation Bio (NUVB) Stock Forecast & Price Target

Compare

673 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NUVB Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Nuvation

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NUVB Stock 12 Month Forecast

Average Price Target

$10.38

▲(29.59% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $10.38 with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 29.59% change from the last price of $8.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,5.741538461538461,6.263076923076923,6.7846153846153845,7.306153846153846,7.827692307692307,8.349230769230768,8.87076923076923,9.392307692307693,9.913846153846153,10.435384615384613,10.956923076923076,11.478461538461538,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,5.616923076923077,6.013846153846154,6.4107692307692306,6.8076923076923075,7.204615384615384,7.601538461538462,7.998461538461539,8.395384615384616,8.792307692307693,9.18923076923077,9.586153846153847,9.983076923076924,{"y":10.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.22,5.4338461538461535,5.647692307692307,5.861538461538461,6.075384615384615,6.289230769230769,6.503076923076923,6.716923076923077,6.930769230769231,7.144615384615385,7.358461538461539,7.572307692307692,7.786153846153846,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$10.38

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

―

Buy

―

Reiterated

11/28/25

Kaveri Pohlman

Clear Street

$12

Buy

49.81%

Upside

Reiterated

11/26/25

Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

$11

Buy

37.33%

Upside

Initiated

11/24/25

Nuvation Bio (NUVB) Gets a Buy from Truist Financial

Silvan Tuerkcan

Citizens JMP

$8→$10

Buy

24.84%

Upside

Reiterated

11/20/25

Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP

David Nierengarten

Wedbush

$7→$11

Buy

37.33%

Upside

Reiterated

11/19/25

Nuvation Bio price target raised to $11 from $7 at WedbushNuvation Bio price target raised to $11 from $7 at Wedbush

Mayank Mamtani

B. Riley Securities

$12

Buy

49.81%

Upside

Initiated

11/19/25

Nuvation Bio initiated with a Buy at B. RileyNuvation Bio initiated with a Buy at B. Riley

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/18/25

Nuvation Bio (NUVB) Receives a Buy from TD Cowen

Soumit Roy

JonesTrading

$10

Buy

24.84%

Upside

Reiterated

11/18/25

Positive Outlook on Nuvation Bio's Safusidenib Driven by Promising Clinical Data and Strategic FocusWe remain highly optimistic regarding NUVB's exciting second program with safusidenib following their first FDA approval with Ibtrozi. Recall that NUVB acquired safusidenib from the acquisition of AnHeart Therapeutics, who licensed the drug from 2024 (press release). This update from Daiichi (OTCMKTS: DSNKY, Not Rated) helped to better clarify safusidenib's durable efficacy, even if mPFS was not reached, and profile in the non-enhancing tumors. However, we note that it is in enhancing tumors where we saw the first complete responses of any Symbol NUVB Price (Nov 17, 2025) 4.67 Market Cap (MM) 1,606 Dividend NA Enterprise Value (MM) 1,114 Shares/Units Outstanding (MM) 342.833 Dividend Yield NA Free Float (MM) 275.6 Free Float % 80.4% 52-Week Range 1.54—5.55 3-Month Avg. Daily Vol.

Robert Burns

H.C. Wainwright

$10

Buy

24.84%

Upside

Reiterated

11/04/25

Nuvation Bio (NUVB) Gets a Buy from H.C. Wainwright

Leonid Timashev

RBC Capital

$7→$8

Buy

-0.12%

Downside

Reiterated

11/03/25

Nuvation Bio (NUVB) Receives a Buy from RBC Capital

Farzin Haque

Jefferies

$10

Buy

24.84%

Upside

Initiated

09/29/25

Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

―

Buy

―

Reiterated

11/28/25

Kaveri Pohlman

Clear Street

$12

Buy

49.81%

Upside

Reiterated

11/26/25

Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued

Unknown Analyst

Truist Financial

Not Ranked

Truist Financial

$11

Buy

37.33%

Upside

Initiated

11/24/25

Nuvation Bio (NUVB) Gets a Buy from Truist Financial

Silvan Tuerkcan

Citizens JMP

$8→$10

Buy

24.84%

Upside

Reiterated

11/20/25

Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP

David Nierengarten

Wedbush

$7→$11

Buy

37.33%

Upside

Reiterated

11/19/25

Nuvation Bio price target raised to $11 from $7 at WedbushNuvation Bio price target raised to $11 from $7 at Wedbush

Mayank Mamtani

B. Riley Securities

$12

Buy

49.81%

Upside

Initiated

11/19/25

Nuvation Bio initiated with a Buy at B. RileyNuvation Bio initiated with a Buy at B. Riley

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/18/25

Nuvation Bio (NUVB) Receives a Buy from TD Cowen

Soumit Roy

JonesTrading

$10

Buy

24.84%

Upside

Reiterated

11/18/25

Robert Burns

H.C. Wainwright

$10

Buy

24.84%

Upside

Reiterated

11/04/25

Nuvation Bio (NUVB) Gets a Buy from H.C. Wainwright

Leonid Timashev

RBC Capital

$7→$8

Buy

-0.12%

Downside

Reiterated

11/03/25

Nuvation Bio (NUVB) Receives a Buy from RBC Capital

Farzin Haque

Jefferies

$10

Buy

24.84%

Upside

Initiated

09/29/25

Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvation Bio

1 Month

xxx

Success Rate

10/17 ratings generated profit

Average Return

+7.51%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +7.51% per trade.

3 Months

xxx

Success Rate

12/17 ratings generated profit

Average Return

+21.86%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +21.86% per trade.

1 Year

David NierengartenWedbush

Success Rate

12/16 ratings generated profit

Average Return

+89.63%

reiterated a buy rating 10 days ago

Copying David Nierengarten's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +89.63% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+153.33%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +153.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVB Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NUVB has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NUVB average Analyst price target in the past 3 months is 10.38.

Each month's total comprises the sum of three months' worth of ratings.

NUVB Financial Forecast

NUVB Earnings Forecast

Next quarter’s earnings estimate for NUVB is -$0.10 with a range of -$0.15 to -$0.08. The previous quarter’s EPS was -$0.16. NUVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Sales Forecast

Next quarter’s sales forecast for NUVB is $32.91M with a range of $14.37M to $49.80M. The previous quarter’s sales results were $13.12M. NUVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Stock Forecast FAQ

What is NUVB’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuvation Bio’s 12-month average price target is 10.38.

What is NUVB’s upside potential, based on the analysts’ average price target?

Nuvation Bio has 29.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NUVB a Buy, Sell or Hold?

Nuvation Bio has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nuvation Bio’s price target?

The average price target for Nuvation Bio is 10.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $8.00. The average price target represents 29.59% Increase from the current price of $8.01.

What do analysts say about Nuvation Bio?

Nuvation Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of NUVB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nuvation Bio (NUVB) Stock Forecast & Price Target

NUVB Analyst Ratings

NUVB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nuvation Bio

NUVB Analyst Recommendation Trends

NUVB Financial Forecast

NUVB Earnings Forecast

NUVB Sales Forecast

NUVB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts